Amylyx Pharmaceuticals (AMLX) Set to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3805) per share and revenue of $0.06 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post ($1.48) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $28.07 on Thursday. The firm’s fifty day moving average is $31.31 and its 200 day moving average is $19.88. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -19.63 and a beta of -0.10. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14.

Wall Street Analyst Weigh In

AMLX has been the subject of several research analyst reports. Citigroup increased their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, October 15th. Robert W. Baird lifted their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Mizuho upped their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright upped their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.71.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director M Jr sold 30,000 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total transaction of $831,000.00. Following the completion of the transaction, the director owned 782,881 shares of the company’s stock, valued at $21,685,803.70. This represents a 3.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gina Mazzariello sold 9,536 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total value of $309,538.56. Following the transaction, the insider owned 190,838 shares of the company’s stock, valued at approximately $6,194,601.48. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 60,374 shares of company stock worth $1,815,257 in the last quarter. 10.90% of the stock is owned by company insiders.

About Amylyx Pharmaceuticals